Hi A***w, I came across your profile and was impressed by your extensive leadership in global business development and licensing at M***k,from Principal Scientist through to Executive Director of Search & Evaluation. I’m J***e, an HR recruiter partnering with B***c, and we’re currently seeking a Senior Vice President of Strategic Partnerships & Licensing. Given your track record driving in-licensing/out-licensing negotiations and building high-performing teams, I believe this role could be an excellent fit. Would you be open to a brief conversation to learn more about the opportunity?

Hi A***w, Great to hear you’d like to connect. Here’s a high-level scope of the SVP, Strategic Partnerships & Licensing role at B***c: • Lead global in-licensing and out-licensing negotiations for novel therapeutic and enabling technology assets • Develop and execute comprehensive BD strategies through rigorous scientific and commercial evaluation • Work cross-functionally with R&D, regulatory and commercial teams to align deals with company goals • Build and mentor a high-caliber business development team • Cultivate and maintain executive-level industry relationships for continuous pipeline replenishment I’m free for a 30-minute call this week on: • Tuesday, 9:00,11:00 AM ET • Wednesday, 2:00,4:00 PM ET Let me know which slot works best (or feel free to propose another), and I’ll send over a calendar invite. Looking forward to our conversation! Best, J***e

Hi A***w, Great,Wednesday at 2:00 PM ET is confirmed. I’ll send a calendar invite shortly. In the meantime, here’s a bit more on B***c and the SVP, Strategic Partnerships & Licensing role,especially around streamlined deal processes. About B***c • Mid-sized biotech (500+ employees) focused on therapeutic and enabling technology innovation • Culture of scientific excellence, collaboration and patient-centric agility How we streamline deals • A dedicated, cross-functional steering committee (R&D, regulatory, commercial) meets on a bi-weekly cadence to fast-track evaluations • Clear decision rights with minimal review layers, enabling time-to-value in weeks, not months • Direct executive sponsorship to resolve roadblocks quickly Role highlights • Lead global in- and out-licensing negotiations for novel therapeutics and platform technologies • Shape and execute BD strategy through rigorous scientific and commercial assessment • Collaborate directly with senior R&D, regulatory and commercial leaders in an agile forum • Build and mentor a high-caliber BD team, fostering innovation and deal-making excellence • Maintain executive-level industry relationships for continuous pipeline replenishment Support & growth • Dedicated deal team (project managers, financial analysts, scientific advisors) • Access to our translational science group for rapid due diligence • Competitive base salary, performance bonus and equity package • Full benefits (healthcare, 401(k) match, generous PTO) • Clear paths for advancement into company-wide strategic roles Given your track record leading global search & evaluation at M***k, I believe you’d thrive in our lean, empowered environment. Does this overview address your interest in more agile deal processes? Let me know if there’s anything you’d like to discuss before our call. Looking forward to speaking on Wednesday! Best regards, J***e HR Recruiter, StrategyBrain / B***c

Hi A***w, Great questions. In this SVP role you’ll report directly to our Chief Business Officer, who sits on the executive leadership team alongside the CEO and COO. Today, the BD/licensing function is part of our dedicated deal team,currently three specialists (a project manager, financial analyst and scientific advisor),and you’ll formalize this into your own Strategic Partnerships & Licensing group, scaling headcount in line with your roadmap and objectives. As for deal approvals, you will have full sign-off authority within pre-defined financial and strategic thresholds. Only exceptionally large or transformational transactions are escalated to the CEO/Executive Committee. We’ve designed our governance (bi-weekly steering committee plus direct executive sponsorship) to ensure you can move deals to closure quickly and with minimal red tape. Hope this helps,looking forward to diving deeper on Wednesday at 2 PM ET. Best, J***e

Hi A***w, Here’s a high-level view of sign-off authority and first-year team and budget planning: 1. Financial & Strategic Sign-Off , You’ll have full approval rights on any in- or out-licensing deals that fall within our board-approved BD budget and core strategic priorities (therapeutic and platform assets). , Only larger, transformational transactions (historically under 10% of deals) or those outside our defined focus areas are escalated to the CBO/Executive Committee. 2. Team Headcount Ramp , You’ll start with the existing three-person deal team and build to roughly 6,8 FTEs over the first 12 months. , Hiring is phased to align with deal flow and strategic milestones (e.g., adding senior BD and analytics roles in Q2,Q3, then specialist advisors in Q4). 3. Budget Allocation , We front-load resources for Q1,Q2 hires and operations, with a contingency pool reserved for late-year expansion and deal-related expenses (travel, external diligence). , Quarterly reviews with the CBO ensure your team’s budget flexes with your priorities. I can share the exact financial thresholds and detailed budget breakdown when you speak with our CBO on Wednesday. Let me know if you’d like any further clarification before then. Looking forward to our call! Best regards, J***e

Hi A***w, Here’s a ballpark breakdown based on our current plan: 1. Year-1 BD Budget • Total allocation: ~$20,25 million, with ~$15 million earmarked for in-licensing and ~$5,10 million reserved for out-licensing and diligence support. • A 10% contingency pool covers travel, external advisors and late-stage deal expenses. 2. Deal-Size Thresholds for SVP Sign-Off • You’ll have full approval authority on deals up to ~$3,5 million per transaction. • Deals between $5,10 million are co-signed with the CBO. • Transactions above $10 million (or outside our core therapeutic/platform focus) are escalated to the Executive Committee,historically <10% of our volume. 3. Phased Hiring & Milestones • Q1: Ramp existing 3-person deal team; close 3,5 small-to-mid-sized deals to validate process. • Q2: Add a senior BD Manager and lead Data & Analytics hire once we hit 5,7 signed deals. • Q3: Onboard 1,2 additional BD Associates as deal flow reaches ~10 active opportunities. • Q4: Bring in specialized advisors (e.g., legal/licensing lead) when overall deal volume exceeds 12,15 transactions. These targets are flexible and reviewed quarterly with the CBO to ensure we’re scaling both headcount and budget in line with your pipeline. I’ll share more granular details when you speak with our CBO on Wednesday, but please let me know if this framework aligns with your expectations or if you’d like any adjustments ahead of our call. Looking forward to it! Best, J***e